Guillermo Montalban‐Bravo

10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial

Courtney D. DiNardo, Abhishek Maiti, Caitlin R. Rausch et al. · The Lancet Haematology · 2020 · 325 citations · Full text

Hematological Malignancy, Medicine, Mixed-phenotype Acute Leukemia +9

Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia

Courtney D. DiNardo, Curtis A. Lachowiez, Koichi Takahashi et al. · Journal of Clinical Oncology · 2021 · 321 citations · Full text

Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial

Elias Jabbour, Nicholas J. Short, Nitin Jain et al. · The Lancet Haematology · 2022 · 215 citations

Hematological Malignancy, Lymphoid Neoplasia, Medicine +6

Myelodysplastic syndromes: 2018 update on diagnosis, risk‐stratification and management

Guillermo Montalban‐Bravo, Guillermo Garcia‐Manero · American Journal of Hematology · 2017 · 214 citations · Full text

Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN

Elias Jabbour, Nicholas J. Short, Guillermo Montalban‐Bravo et al. · Blood · 2017 · 178 citations · Full text